PolyPidPYPD +2.73%33 EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus rates PYPD with a GF Score™ of 33/100. The stock has 1 warning sign investors should review. Among 944 Biotechnology companies, PolyPid ranks worse than 105932.1% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. PolyPid's EBITDA for the
three
months ended in Mar. 2026 was $-7.76 Mil. PolyPid's Revenue for the
three
months ended in Mar. 2026 was $0.00 Mil. Therefore, PolyPid's EBITDA margin for the quarter that ended in Mar. 2026 was 0.00%.
PolyPid (NAS:PYPD) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
PolyPid EBITDA Margin % Related Terms
PolyPid EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for PolyPid's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PYPD vs LONA, ANIX, SGMO: EBITDA Margin % Comparison
For the Biotechnology subindustry, PolyPid's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PolyPid EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, PolyPid's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where PolyPid's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PolyPid (PYPD) has a EBITDA Margin % of 0.00% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on PolyPid and its competitors. According to the industry distribution chart, PolyPid ranks #999999 out of 944 companies in the Biotechnology industry.
Is PolyPid's EBITDA Margin % too high?
PolyPid's current EBITDA Margin % is 0.00%. Based on the distribution chart, PolyPid ranks #999999 out of 944 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, PolyPid has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does PolyPid's EBITDA Margin % compare to LONA and ANIX?
According to the Biotechnology industry distribution chart, PolyPid ranks #999999 out of 944 companies for EBITDA Margin %. This places PolyPid in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on PolyPid and its competitors. PolyPid's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PolyPid stock overvalued right now?
PolyPid (PYPD) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. PolyPid's overall GF Score™ is 33/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For PolyPid (PYPD), the current EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. The company's product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.
33GF Score
Get the complete analysis for PYPD
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PYPD has been successfully added to your 
